{"filing":{"accession_number":"0001214659-26-011688","cik":"0001643918","ticker":"BDRX","company_name":"Biodexa Pharmaceuticals Plc","form":"6-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"i9142616k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1643918/000121465926011688/i9142616k.htm"},"events":[{"id":33500,"run_id":30802,"accession_number":"0001214659-26-011688","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Biodexa announced entry into a warrant exercise transaction involving issuance of new unregistered warrants to purchase 4,408,436 ADSs at $1.05 exercise price in a private placement to an accredited investor. The New Warrants were offered pursuant to an exemption from Securities Act registration and have not been registered, fitting the dilutive_issuance profile. The transaction generates $2.3 million in gross proceeds and creates substantial dilution through warrant inducement, a common capital-raising mechanism at clinical-stage biotech companies.","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-09-15","form":"6-K","submitted_at":null,"items":[{"id":36960,"accession_number":"0001214659-26-011688","item_number":"EX-99.1","item_title":"ex99_1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Biodexa announced entry into a warrant exercise transaction involving issuance of new unregistered warrants to purchase 4,408,436 ADSs at $1.05 exercise price in a private placement to an accredited investor. The New Warrants were offered pursuant to an exemption from Securities Act registration and have not been registered, fitting the dilutive_issuance profile. The transaction generates $2.3 million in gross proceeds and creates substantial dilution through warrant inducement, a common capital-raising mechanism at clinical-stage biotech companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:28:59.277463+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36960,"accession_number":"0001214659-26-011688","item_number":"EX-99.1","item_title":"ex99_1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Biodexa announced entry into a warrant exercise transaction involving issuance of new unregistered warrants to purchase 4,408,436 ADSs at $1.05 exercise price in a private placement to an accredited investor. The New Warrants were offered pursuant to an exemption from Securities Act registration and have not been registered, fitting the dilutive_issuance profile. The transaction generates $2.3 million in gross proceeds and creates substantial dilution through warrant inducement, a common capital-raising mechanism at clinical-stage biotech companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:28:59.277463+00:00","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-09-15"}]}